Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC


  • The University of Rochester Clinical & Translational Science Institute (UR CTSI) was one of the first 12 institutions to be funded by the Clinical and Translational Science Award Program at the National Institutes of Health. Since its inception in 2006, the UR CTSI has been continually funded by the CTSA program, which is now administered by the National Center for Advancing Translational Sciences. In its first ten years, the UR CTSI provided pilot funding and training that helped researchers and students secure approximately $58 million in additional external funding to advance their studies. 
  • Health Sciences Center for Computational Innovation (HSCCI)
    The intersection of science, medicine, and computational technology holds unsurpassed promise and importance in the 21st century. At that juncture, the Health Sciences Center for Computational Innovation (HSCCI) facilitates access to high-performance computational resources for biomedical research.
    Home to IBM's latest supercomputer, the BlueGene/Q, and a new Linux cluster, BlueHive 2, HSCCI is one of the five most powerful university-based supercomputing sites in the nation. Construction of a state-of-the-art visualization lab was completed in June 2014. The combination of cutting-edge equipment and expert staff allows University researchers to focus on solving health care's most complex problems.
  • Goergen Data Science Institute is located in Wegmans Hall, the Goergen Institute for Data Science is home to interdisciplinary data science research and the interdepartmental data science academic programs. 
  • Department of Microbiology and Immunology
  • David H. Smith Center for Vaccine Biology and Immunology
  • Respiratory Pathogens Research Center (RPRC)
    The role of the RPRC is to provide the NIAID Division of Microbiology and Infectious Diseases (DMID) with the capability of conducting translational and clinical research focused on the development and optimization of control measures for viral and bacterial respiratory pathogens. Research conducted under the RPRC shall focus primarily on the development of information, tools, and strategies to decrease the significant global health burden of diseases, such as bacterial pneumonia, influenza, bronchiolitis, and RSV. This also includes studies on viral-bacterial co-infections. Activities include the design, conduct, and analysis of translational, clinical, and innovation research projects. Studies within this Center will be iterative in that results from translational studies will help better inform the design and/or conduct of clinical studies and vice versa. Respiratory pathogens of primary focus include influenza viruses, respiratory syncytial virus (RSV), human coronaviruses, human metapneumoviruses, parainfluenza viruses, Group A Streptococcus, Pneumococcus, Bordetella pertussis, as well as emerging and re-emerging respiratory pathogens.
  • Facility for the Evaluation of Vaccines at the University or Rochester (FEVUR) is supported by a contract with the intramural Laboratory of Infectious Diseases, and is primarily designed to conduct clinical evaluation of candidate pandemic live attenuated influenza vaccines.  These vaccines are constructed using the same master donor virus (MDV) that is used to construct seasonal live influenza vaccines, but possess novel hemagglutinin (HA) and neuraminidase (NA) envelope glycoproteins such as H2N3, H5N1, H7N7 or H7N9.  Because of the theoretical risk that such live vaccines could be transmitted from person to person, clinical studies of these vaccines are conducted in a dedicated isolation facility where study subjects can be housed during the period that they are shedding the vaccine virus.  Some studies have also included administration of related inactivated vaccines, and are accompanied by intensive studies of the cellular, humoral, and mucosal immune response.